Having trouble accessing articles? Reset your cache.

Mipomersen: Additional Phase III data

Additional data from the double-blind, North American Phase III RADICHOL II trial in 124 patients showed that once-weekly subcutaneous injections of 200 mg mipomersen significantly reduced APOB by 26% from baseline to week 26 vs. a 7% increase for placebo (p<0.001). Mipomersen

Read the full 427 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE